Major Insider Samir Patel Invests $688K in Akari Therapeutics Warrants, Boosting Stake to 10.4%

summarizeSummary

Samir R. Patel, a key insider and manager of PranaBio Investments LLC, disclosed a significant personal investment of approximately $688,420 in Akari Therapeutics' Series G, Prefunded, and Note Exchange Warrants, increasing his beneficial ownership to 10.4%.

check_boxKey Events · Ownership and Investor Activity · AKTX

• Significant Insider Investment

  Samir R. Patel, a key insider and manager of PranaBio Investments LLC, invested approximately $688,420 of personal funds into Akari Therapeutics.

• Warrant and Prefunded Warrant Purchase

  The investment was made through the purchase of Series G, Prefunded, and Note Exchange Warrants on December 17, 2025, at a combined price of $0.4041 per warrant pair.

• Increased Beneficial Ownership

  This transaction increases Dr. Patel's beneficial ownership in Akari Therapeutics to 10.4% of the outstanding ordinary shares.

• Context of Potential Dilution

  This substantial insider purchase occurs shortly after shareholders approved the exercisability of warrants, which could lead to significant dilution, signaling strong confidence from a major stakeholder.

auto_awesomeAnalysis · AKTX · Life Sciences

This Schedule 13D/A reveals a substantial personal investment by Samir R. Patel, a significant insider and manager of PranaBio Investments LLC, into Akari Therapeutics. The purchase of Series G, Prefunded, and Note Exchange Warrants, totaling approximately $688,420, represents a considerable capital injection relative to the company's small market capitalization. This move demonstrates strong insider confidence, especially following the recent shareholder approval for warrant exercisability which could lead to significant dilution. Patel's increased beneficial ownership to 10.4% signals a long-term commitment and could be viewed positively by investors as the company navigates its financing needs.